Nanobiotix stock declines following its 349% surge over one year
The Parisian biotech company is retreating sharply in this first trading session of the week, once again ranking among the most affected securities in the broader index. The decline occurs in a nearly stable market, with the SBF 120 trading practically flat during the session.
A decline of nearly 3% that brings the stock back towards its short-term moving averages
Nanobiotix is down 2.87% to €35.22 during trading, after closing at €36.26 in the previous session (Friday, August 28). The stock remains, however, above its 20-day moving average, which stands at €34.93, with a positive spread of 0.83%. It is also maintaining its position above its 50-day moving average at €33.95 (+3.74%), which reflects a still-favorable configuration over the medium term despite today's decline.
Over one year, performance remains spectacular: the stock has advanced nearly 349%, even though the past week was marked by a loss of 7.41%. The RSI at 54 remains in neutral territory, with no oversold signal for the time being, which leaves the technical configuration in a middle ground after the recent high volatility. Resistance at €38.60 and support at €31.28 now frame the levels to monitor for the next move.
An eventful week for the stock, caught in a succession of declines and rebounds
Monday's session falls within a particularly volatile sequence. On Friday, August 28, the stock posted the worst performance of the SBF 120, declining more than 5% after briefly breaking through its resistance level at the start of the session before retreating quickly. The day before, Thursday, August 27, the biotech had posted one of the best gains on the French market, advancing nearly 6% against the grain of a declining market. This alternation of marked gains and losses reflects a high monthly volatility of 24.73%. Over one month, the balance sheet remains positive at +4.02%, which puts the week's decline into perspective.
The SBF 120 is trading practically flat during the session (-0.02%), so Nanobiotix's decline is specific to the stock itself. Among comparable securities in the healthcare sector, Sanofi is down 0.19% and Eurofins Scientific is declining 0.22%, variations that pale in comparison to the amplitude observed on this stock. Support at €31.28 represents the next reference floor in the event of a continued decline.
